Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial
Nicolas Girard, Françoise Mornex, Jean-Yves Douillard, Nadine Bossard, Elisabeth Quoix, Véronique Beckendorf, Dominique Grunenwald, Elodie Amour, Bernard Milleron
20100601
2010 Jul 1
Lung Cancer
Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial
Lung Cancer. 2010 Jul;69(1):86-93, Nicolas Girard, Françoise Mornex, Jean-Yves Douillard, Nadine Bossard, Elisabeth Quoix, Véronique Beckendorf, Dominique Grunenwald, Elodie Amour, Bernard Milleron
Locally advanced non-small cell lung cancers share a risk of both local and systemic recurrence and justifies a therapeutic strategy combining focal and systemic treatment. In resectable stage IIIA-N2 tumors, peri-operative chemotherapy significantly increases survival rates. Chemoradiotherapy, which is the standard treatment of non-resectable locally advanced tumors, may have a role as an induction treatment to reduce locoregional recurrence rates.In the present phase II trial, we aimed at comparing...
Editors' Choice
Long-Term Posttransplant Bortezomib Boosts Outcome in Myeloma With del(17p13)
